The pre-clinical and under-clinical subunit protein TB vaccine candidates are inherently a CD4+ T cell-targeting platform with an emphasis target on protective multifunctional Th1 cells which are the major IFN-γ secreting cells in humans. This evidence concerns the gene IFNG and tuberculosis.